The St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) system with directional lead technology is designed to help patients with Parkinson’s disease or essential tremor gain control of their ...

Shabbar Danish, chief, Neurosurgery, Rutgers Cancer Institute, and director of Stereotactic and Functional Neurosurgery at RWJUH, successfully implanted the device in the first patient Oct. 25 at ...

Medtronic (NYSE: MDT) announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering.

The US Food and Drug Administration (FDA) has approved a new software upgrade for Abbott's Infinity deep-brain stimulation (DBS) system used in patients with Parkinson's disease and essential tremor, ...

NEW ORLEANS — A new multiple-source system for deep-brain stimulation (DBS) in patients with Parkinson's disease proved effective in the randomized, double-blind INTREPID trial, meeting its primary ...

Medtronic plc MDT recently announced receipt of the FDA’s approval for its Percept PC Deep Brain Stimulation (“DBS”) system. The inclusion of the BrainSense technology with the Percept PC DBS system ...

St. Jude Medical Inc.STJ recently announced the receipt of CE Mark approval for its Infinity Deep Brain Stimulation ("DBS") System and directional DBS lead, allowing sale in the European market. The ...

Newronika has completed a €13.6m ($14.1m) Series B funding to advance the development of AlphaDBS, an adaptive deep brain stimulation (DBS) system for addressing the symptoms of Parkinson’s disease.

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the United States Food and Drug Administration approval and first implant of the ...